Hospital
Kaleida Health
Kaleida Health was paid $30.80M by Medicaid between Jan 2018 and Dec 2024, across 301 billing codes. Its largest line is G0378, Hospital observation service, per hour — 14% of everything it billed.
33Billing provider infoKALEIDA HEALTH
BUFFALO, NY 14203
BUFFALO, NY 14203
33aNPI1639209596assigned 03/07/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.80M
24GClaims790,874
24DCodes billed301
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#43 of 231
Median peer was paid$561K
This provider vs. median55×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 973 | $54K | |
| 2019 | 43,252 | $1.25M | |
| 2020 | 68,174 | $2.63M | |
| 2021 | 137,143 | $5.26M | |
| 2022 | 178,835 | $7.57M | |
| 2023 | 196,754 | $7.86M | |
| 2024incomplete | 165,743 | $6.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 14% | 3,227 | 3,099 | $4.23M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.0% | 11,978 | 11,258 | $2.46M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.7% | 12,582 | 11,943 | $2.36M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 12,191 | 11,556 | $1.95M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.8% | 17,989 | 16,616 | $1.49M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.0% | 12,948 | 11,974 | $1.22M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.6% | 5,987 | 5,557 | $1.12M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 5,397 | 4,903 | $1.08M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 7,718 | 7,305 | $957K |
| 80053 | Comprehensive metabolic panel | 3.0% | 63,549 | 48,976 | $929K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.7% | 1,279 | 1,268 | $826K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 3,907 | 3,776 | $720K |
289 more codes
| 93458 | 2.2% | 424 | $671K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.9% | 20,914 | $582K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 20,705 | $506K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 2,028 | $487K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.5% | 590 | $467K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.2% | 17,448 | $369K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 4,690 | $366K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.1% | 13,534 | $351K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.1% | 13,186 | $328K |
| 87631 | <1% | 6,212 | $302K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 715 | $270K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,752 | $248K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,772 | $247K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,147 | $233K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,122 | $226K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,964 | $223K |
| 87481 | <1% | 3,277 | $199K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 7,355 | $188K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 903 | $170K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 629 | $162K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,104 | $158K |
| 70496 | <1% | 869 | $158K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,303 | $149K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 906 | $145K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,138 | $140K |
| 99442 | <1% | 1,200 | $136K | |
| 80061 | Lipid panel | <1% | 15,584 | $132K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,237 | $128K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,986 | $128K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 982 | $127K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 47,800 | $126K |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,748 | $120K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 513 | $106K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,631 | $106K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,392 | $102K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,024 | $94K |
| 83880 | <1% | 3,833 | $93K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,400 | $90K |
| 84153 | <1% | 4,745 | $82K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,588 | $79K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 119 | $72K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 402 | $69K |
| 87070 | <1% | 8,551 | $61K | |
| 86900 | <1% | 3,559 | $58K | |
| 81513 | <1% | 1,976 | $56K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,398 | $55K |
| 99443 | <1% | 488 | $54K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 385 | $51K |
| 93975 | <1% | 86 | $47K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 413 | $47K |
| 82803 | <1% | 2,300 | $47K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,688 | $45K |
| 97161 | <1% | 1,044 | $43K | |
| 82607 | <1% | 3,684 | $43K | |
| 84439 | <1% | 5,350 | $43K | |
| 81025 | <1% | 11,799 | $43K | |
| 97803 | <1% | 2,253 | $43K | |
| 96127 | <1% | 4,242 | $39K | |
| 87077 | <1% | 4,451 | $37K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,084 | $37K |
| 86850 | <1% | 3,540 | $37K | |
| 93017 | <1% | 802 | $36K | |
| 86901 | <1% | 3,529 | $35K | |
| 86780 | <1% | 3,575 | $35K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 40 | $34K |
| 88342 | <1% | 537 | $31K | |
| 86141 | <1% | 3,957 | $31K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,259 | $31K |
| 86003 | <1% | 476 | $31K | |
| 0042T | <1% | 587 | $29K | |
| 84403 | <1% | 1,167 | $28K | |
| 81001 | <1% | 16,515 | $28K | |
| 99406 | <1% | 956 | $28K | |
| 87186 | <1% | 4,068 | $27K | |
| 85610 | <1% | 11,359 | $26K | |
| 82728 | <1% | 2,178 | $25K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 629 | $25K |
| 83735 | <1% | 9,296 | $25K | |
| 87147 | <1% | 1,680 | $24K | |
| 86480 | <1% | 461 | $24K | |
| 82746 | <1% | 2,248 | $24K | |
| 83874 | <1% | 7,182 | $22K | |
| 85027 | <1% | 6,841 | $22K | |
| 87088 | <1% | 3,410 | $22K | |
| C1769 | Guide wire | <1% | 1,348 | $21K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,238 | $21K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,203 | $18K |
| 86803 | <1% | 2,212 | $17K | |
| 82043 | <1% | 3,406 | $16K | |
| 76000 | <1% | 428 | $16K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 627 | $16K |
| 82570 | <1% | 3,789 | $16K | |
| 85730 | <1% | 5,777 | $16K | |
| 87660 | <1% | 1,195 | $16K | |
| 90715 | <1% | 489 | $15K | |
| 87480 | <1% | 1,197 | $14K | |
| 87510 | <1% | 1,193 | $14K | |
| 97162 | <1% | 239 | $14K | |
| 83690 | <1% | 5,213 | $14K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 94 | $14K |
| 83540 | <1% | 2,676 | $13K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,227 | $12K |
| 83970 | <1% | 270 | $11K | |
| 86762 | <1% | 772 | $11K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 257 | $11K |
| 74174 | <1% | 41 | $11K | |
| 82784 | <1% | 667 | $10K | |
| 3077F | <1% | 466 | $10K | |
| 83550 | <1% | 2,017 | $10K | |
| 94726 | <1% | 417 | $10K | |
| 83001 | <1% | 620 | $10K | |
| 70498 | <1% | 591 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 427 | $10K |
| 90686 | <1% | 315 | $10K | |
| 86769 | <1% | 529 | $9K | |
| 83655 | <1% | 729 | $9K | |
| 83605 | <1% | 3,551 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,813 | $9K |
| 85651 | <1% | 4,472 | $9K | |
| 94729 | <1% | 507 | $8K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,043 | $8K |
| 96376 | <1% | 1,626 | $8K | |
| 70486 | <1% | 84 | $8K | |
| 87522 | Neg quan hep c or qual rna | <1% | 201 | $8K |
| 83002 | <1% | 456 | $7K | |
| 84154 | <1% | 435 | $7K | |
| 84146 | <1% | 424 | $7K | |
| 84702 | <1% | 750 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 643 | $7K |
| 71250 | <1% | 65 | $7K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 70 | $7K |
| 86038 | <1% | 1,006 | $7K | |
| 93308 | <1% | 38 | $6K | |
| 3074F | <1% | 320 | $6K | |
| 84134 | <1% | 737 | $6K | |
| 73564 | <1% | 910 | $6K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 220 | $6K |
| 94010 | <1% | 432 | $6K | |
| 82785 | <1% | 401 | $6K | |
| 86706 | <1% | 608 | $6K | |
| 84703 | <1% | 1,913 | $6K | |
| 82948 | <1% | 4,310 | $5K | |
| 87340 | <1% | 637 | $5K | |
| 84484 | <1% | 9,900 | $5K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 38 | $5K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 124 | $4K |
| 11721 | <1% | 195 | $4K | |
| C9399 | Unclassified drugs or biologicals | <1% | 345 | $4K |
| 99205 | Prolong outpt/office vis | <1% | 29 | $4K |
| 97802 | <1% | 183 | $4K | |
| 87210 | <1% | 1,304 | $4K | |
| 20610 | <1% | 13 | $4K | |
| 86765 | <1% | 319 | $4K | |
| 84550 | <1% | 881 | $4K | |
| 84436 | <1% | 844 | $3K | |
| 86376 | <1% | 244 | $3K | |
| 88304 | <1% | 226 | $3K | |
| 84100 | <1% | 1,194 | $3K | |
| 72141 | <1% | 16 | $3K | |
| 84402 | <1% | 127 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,521 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,424 | $3K |
| 86735 | <1% | 320 | $3K | |
| 84481 | <1% | 277 | $3K | |
| 85008 | <1% | 367 | $3K | |
| 73030 | <1% | 636 | $3K | |
| 81003 | <1% | 1,886 | $3K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 271 | $3K |
| 87184 | <1% | 496 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 79 | $3K |
| 88112 | <1% | 85 | $3K | |
| 80320 | <1% | 968 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 109 | $3K |
| 86431 | <1% | 533 | $3K | |
| 73502 | <1% | 544 | $2K | |
| 73630 | <1% | 710 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 801 | $2K |
| 82550 | <1% | 909 | $2K | |
| 80348 | <1% | 483 | $2K | |
| 85032 | <1% | 1,340 | $2K | |
| 97116 | <1% | 124 | $2K | |
| 86800 | <1% | 165 | $2K | |
| 97165 | <1% | 40 | $2K | |
| 94760 | <1% | 1,233 | $2K | |
| 80076 | <1% | 304 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 40 | $2K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 235 | $2K |
| 72100 | <1% | 218 | $2K | |
| 88313 | <1% | 145 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 26 | $2K |
| 3075F | <1% | 55 | $2K | |
| 87040 | <1% | 790 | $2K | |
| 88341 | <1% | 27 | $2K | |
| 73562 | <1% | 243 | $1K | |
| 90688 | <1% | 86 | $1K | |
| 81002 | <1% | 1,023 | $1K | |
| 87625 | <1% | 464 | $1K | |
| 99441 | <1% | 32 | $1K | |
| 82565 | <1% | 867 | $1K | |
| 86039 | <1% | 165 | $1K | |
| 83721 | <1% | 389 | $1K | |
| 86787 | <1% | 102 | $993.01 | |
| 87181 | <1% | 130 | $934.02 | |
| 82150 | <1% | 201 | $931.70 | |
| 85018 | <1% | 649 | $923.37 | |
| 86618 | <1% | 57 | $919.35 | |
| 84480 | <1% | 168 | $909.21 | |
| 73610 | <1% | 328 | $903.97 | |
| 86696 | <1% | 49 | $892.09 | |
| 94060 | <1% | 26 | $879.78 | |
| 69210 | <1% | 21 | $843.81 | |
| 83993 | <1% | 66 | $778.88 | |
| 82670 | <1% | 26 | $777.03 | |
| 72110 | <1% | 128 | $745.71 | |
| 85379 | <1% | 605 | $745.11 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,742 | $641.43 |
| 73130 | <1% | 429 | $594.80 | |
| 86592 | <1% | 221 | $565.12 | |
| 86255 | <1% | 74 | $526.01 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 53 | $515.95 |
| 82140 | <1% | 58 | $504.67 | |
| 84156 | <1% | 135 | $489.43 | |
| 86704 | <1% | 58 | $480.03 | |
| 90656 | <1% | 20 | $421.34 | |
| 82787 | <1% | 16 | $357.83 | |
| 88302 | <1% | 12 | $327.80 | |
| 73110 | <1% | 97 | $322.87 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 26 | $306.71 |
| 86738 | <1% | 13 | $294.70 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,869 | $291.91 |
| 74018 | <1% | 31 | $237.06 | |
| 87075 | <1% | 50 | $219.98 | |
| 84460 | <1% | 41 | $199.69 | |
| 89190 | <1% | 37 | $183.68 | |
| 84450 | <1% | 38 | $182.94 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,875 | $167.88 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,254 | $157.62 |
| 87081 | <1% | 58 | $151.82 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,417 | $140.13 |
| 82950 | <1% | 27 | $133.65 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,054 | $132.10 |
| 85347 | <1% | 25 | $125.29 | |
| 82977 | <1% | 24 | $121.95 | |
| 87338 | <1% | 13 | $116.35 | |
| 87400 | <1% | 297 | $113.60 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,365 | $104.92 |
| 80361 | <1% | 21 | $97.87 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,293 | $89.20 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 219 | $88.76 |
| 87101 | <1% | 25 | $86.82 | |
| 86710 | <1% | 255 | $84.17 | |
| 85045 | <1% | 31 | $70.33 | |
| 80177 | <1% | 12 | $69.70 | |
| 82248 | <1% | 13 | $60.60 | |
| 83615 | <1% | 15 | $58.10 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 96 | $57.01 |
| 87430 | <1% | 246 | $55.36 | |
| 84520 | <1% | 12 | $47.94 | |
| 73590 | <1% | 31 | $45.52 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,000 | $44.75 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 408 | $44.22 |
| 87449 | <1% | 13 | $43.86 | |
| 73080 | <1% | 13 | $41.80 | |
| 82010 | <1% | 74 | $40.14 | |
| 89051 | <1% | 14 | $37.46 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,741 | $33.38 |
| 87324 | <1% | 12 | $30.51 | |
| 82945 | <1% | 12 | $26.82 | |
| 84157 | <1% | 12 | $25.76 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 199 | $23.20 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 40 | $21.79 |
| 74022 | <1% | 24 | $16.07 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 969 | $12.62 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 60 | $9.86 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 25 | $8.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 657 | $6.74 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 215 | $4.03 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 85 | $2.44 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 12 | $0.26 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 218 | $0.12 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 75 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 43 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 27 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 13 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 112 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 86 | $0.00 |
| 80329 | 0% | 14 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCROREY, ANGELA (AR MANAGER)
Parent organizationKALEIDA HEALTH
| Provider | Location | Paid |
|---|---|---|
| Kaleida Health | Buffalo, NY | $80.65M |
| Kaleida Health | Williamsville, NY | $11.67M |
| Kaleida Health | North Tonawanda, NY | $5.40M |
| Kaleida Health | Buffalo, NY | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.